Chardan Capital Markets has recently reduced Outlook Therapeutics Inc (OTLK) stock to Neutral rating, as announced on December 2, 2024, according to Finviz. Earlier, on March 27, 2024, BTIG Research ...

In a report released today, Julian Harrison from BTIG maintained a Buy rating on Outlook Therapeutics (OTLK – Research Report), with a price ...

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report ...

On Friday, Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $1.97 which represents a slight increase of $0.27 or 15.88% from the prior close of $1.7. The stock opened at $1 ...

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...

Pharmaust Limited (AU:NUZ) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Outlook Therapeutics, Inc. ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European ...

Chardan analyst Daniil Gataulin downgraded Outlook Therapeutics (OTLK) to Neutral from Buy without a price target after the company reported preliminary topline efficacy and safety data from the ...

Fintel reports that on December 11, 2024, JMP Securities downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX) ...

The positive NICE recommendation was based on results from Outlook Therapeutics’ wet AMD clinical program for ONS-5010 / LYTENAVA™, which consists of three completed registration clinical ...

Fintel reports that on December 10, 2024, BTIG downgraded their outlook for Carisma Therapeutics (NasdaqGM:CARM) from Buy to ...